氨氯地平联合阿托伐他汀钙片治疗高血压合并冠心病的效果分析  

Effect analysis of amlodipine combined with atorvastatin calcium tablets in the treatment of hypertension complicated with coronary heart disease

作　　者：谢博[1] 吕薇薇 XIE Bo;LYU Wei-wei(Xiji County People's Hospital,Guyuan 756299,China)

机构地区：[1]西吉县人民医院,756299

出　　处：《中国实用医药》2022年第25期10-13,共4页China Practical Medicine

摘　　要：目的 观察氨氯地平联合阿托伐他汀钙片治疗高血压合并冠心病的临床效果。方法 100例高血压合并冠心病患者,按随机数字表法分为对照组和观察组,各50例。对照组采用氨氯地平治疗,观察组采用氨氯地平联合阿托伐他汀钙片治疗。比较两组患者治疗前后血压、心率、心功能指标及治疗效果、不良反应发生情况、治疗认可度。结果 治疗后,两组舒张压、收缩压、心率均低于治疗前,且观察组舒张压(80.26±7.27)mm Hg(1 mm Hg=0.133 kPa)、收缩压(124.46±10.18)mm Hg、心率(81.55±6.13)次/min均低于对照组的(89.18±8.31)mm Hg、(131.18±11.17)mm Hg、(97.47±9.21)次/min,差异具有统计学意义(P<0.05)。治疗后,两组左心室射血分数、左心室收缩末期内径、左心室舒张末期内径均优于治疗前,且观察组左心室射血分数(55.33±3.87)%、左心室收缩末期内径(30.26±4.14)mm、左心室舒张末期内径(50.14±6.12)mm均优于对照组的(48.88±4.38)%、(37.92±5.64)mm、(53.46±5.57)mm,差异具有统计学意义(P<0.05)。观察组治疗总有效率94.00%高于对照组的76.00%,差异具有统计学意义(P<0.05)。观察组不良反应发生率6.00%低于对照组的20.00%,差异有统计学意义(P<0.05)。观察组治疗认可度92.00%高于对照组的72.00%,差异有统计学意义(P<0.05)。结论 氨氯地平联合阿托伐他汀钙片治疗高血压合并冠心病的效果理想,可有效降低血压并改善心功能,且不良反应少,患者对治疗认可度高,值得临床推广。Objective To observe the clinical effect of amlodipine combined with atorvastatin calcium tablets in the treatment of hypertension complicated with coronary heart disease. Methods A total of 100 patients with hypertension and coronary heart disease were divided into control group and observation group according to random numerical table, with 50 cases in each group. The control group was treated with amlodipine,and the observation group was treated with amlodipine combined with atorvastatin calcium tablets. The blood pressure, heart rate and cardiac function indexes before and after treatment, therapeutic effect, occurrence of adverse reactions, and treatment approval were compared between the two groups. Results After treatment,the diastolic blood pressure, systolic blood pressure and heart rate in both groups were lower than those before treatment in this group;the diastolic blood pressure(80.26±7.27) mm Hg(1 mm Hg=0.133 kPa), systolic blood pressure(124.46±10.18) mm Hg and heart rate(81.55±6.13) times/min in the observation group were lower than(89.18±8.31) mm Hg,(131.18±11.17) mm Hg and(97.47±9.21) times/min in the control group;the differences were all statistically significant(P<0.05). After treatment, the left ventricular ejection fraction, left ventricular end-systolic diameter and left ventricular end-diastolic diameter of the two groups were better than those of this group before treatment;the left ventricular ejection fraction(55.33±3.87)%, left ventricular end-systolic diameter(30.26±4.14) mm and left ventricular end-diastolic diameter(50.14±6.12) mm in the observation group were better than(48.88±4.38)%,(37.92±5.64)mm and(53.46±5.57) mm in the control group;the differences were all statistically significant(P<0.05). The total effective rate 94.00% of the observation group was higher than 76.00%of the control group, and the difference was statistically significant(P<0.05). The incidence of adverse reactions 6.00% in the observation group was lower than 20.00% in the control group, and the

关 键 词：氨氯地平 阿托伐他汀钙片 高血压 冠心病 

分 类 号：R541.4[医药卫生—心血管疾病] R544.1[医药卫生—内科学]